Aurinia Pharmaceuticals (AUPH) FCF Margin (2020 - 2026)

Aurinia Pharmaceuticals has reported FCF Margin for 7 years, with the latest figure at 41.85% in Q1 2026.

• For the quarter ending Q1 2026, FCF Margin rose 3980.0% year-over-year to 41.85%; the trailing twelve-month figure through Mar 2026 stood at 55.87% (up 2999.0% YoY), and the FY2025 full-year result was 47.84%, up 2908.0% from the prior year.
• FCF Margin for Q1 2026 stood at 41.85%, down from 59.13% in the prior quarter.
• The five-year high for FCF Margin was 63.05% in Q2 2025, with the low at 216.53% in Q1 2022.
• Historically, FCF Margin has averaged 6.36% across 5 years, with a median of 25.0% in 2024.
• Annual changes were most pronounced in 2022 — FCF Margin surged 575502 bps — and 2023, when it tumbled 520 bps.
• Aurinia Pharmaceuticals' FCF Margin stood at 36.28% in 2022, then declined by 14 bps to 31.07% in 2023, then jumped by 62 bps to 50.21% in 2024, then climbed by 18 bps to 59.13% in 2025, then decreased by 29 bps to 41.85% in 2026.
• The last three FCF Margin figures came in at 41.85% (Q1 2026), 59.13% (Q4 2025), and 60.41% (Q3 2025), per Business Quant data.